Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
by GlobeNewswire
Sep 27, 2024 7:06 pm
Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved lung function and also improved health-related quality of life
COPD is the most prevalent chronic respiratory disease in China, and is a priority within the government's Healthy China 2030 public health plan